首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

2037811

生物製藥契約製造市場（第七版）：按服務類型、生產的生物製劑類型、使用的表達系統、業務規模、公司規模、治療領域和主要區域分類的趨勢和預測（至2035年）

Biologics Contract Manufacturing Market (7th Edition) by Type of Service Offered, Type of Biologic Manufactured, Expression System Used, Scale of Operation, Company Size, Therapeutic Area, Key Geographical Regions - Trends and Forecast, Till 2035

出版日期: 2026年05月07日 | 出版商:

Roots Analysis | 英文 575 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

生物製藥契約製造市場概覽

根據 Roots Analysis 的研究，預計到 2035 年，全球生物製藥契約製造市場將以 8.3% 的複合年成長率成長，達到 639 億美元，高於目前的 310 億美元。

生物製藥契約製造市場：成長與趨勢

生物製藥是生物來源或由生物原料半合成的治療產品。由於它們通常具有超過1000道爾頓的複雜聚合物結構，這些產品往往超出了傳統化學合成的範疇，因此相關相關人員需要投資先進的生物技術平台，以實現可擴展和高效的生產。

慢性病盛行率的不斷上升，以及對先進治療方法的日益重視，正顯著加速生物製藥研發的需求。為此，許多研發公司將生產營運外包給專業的第三方服務供應商，以滿足不斷成長的產能需求並提高營運效率。這種外包策略尤其能夠擴大產能、取得技術專長並豐富產品系列。在眾多外包服務中，分析測試、毒性評估以及填充和包裝流程是關鍵服務領域。

此外，生物製藥和普通藥品的契約製造以及下游研發的需求持續成長。為了抓住這些機遇，中小服務供應商正積極提升自身技術能力，並與合約研發生產機構（CDMO）建立策略夥伴關係，以拓展服務範圍。隨著外包作為一種策略性和成本效益高的經營模式被更廣泛地接受，預計全球生物製藥契約製造市場在預測期內將保持強勁成長。

成長要素－市場擴張的策略促進因素

生物製藥契約製造市場的發展動力源於先進生物製程技術的不斷進步，例如一次性生物反應器、連續灌注系統和人工智慧驅動的自動化系統。這些技術的應用無需對現有基礎設施進行大量資本投入。契約製造機構 (CMO) 正在大力投資建造新一代生產設施，以提供先進的技術能力，從而提高產量、最大限度地降低污染風險並實現快速規模化生產。

此外，這些服務供應商提供高度的營運柔軟性，使企業能夠有效率地調整生產規模，以應對不斷變化的市場需求和突發挑戰。外包生產營運還能透過降低管理費用和營運負擔，顯著提高成本效益。這使得生物製藥公司能夠將更多資源投入核心業務，特別是研發領域。總而言之，這種模式既有利於創新，又有利於成本最佳化，從而提升了產業的價值提案。

市場挑戰－阻礙進展的主要障礙

生物製藥的契約製造市場面臨許多結構性和營運性挑戰，這些挑戰可能會限制其成長軌跡。其中一個主要問題是生物製藥生產的高度複雜性。這需要嚴格的流程控制、專門的基礎設施和熟練的技術人員，從而導致批次失敗和偏差的風險更高。此外，跨多個司法管轄區的監管合規仍然是一大障礙，往往會導致核准延遲和營運成本增加。

尤其是在大規模商業化生產中，產能限制和較長的前置作業時間進一步限制了合約研發生產機構（CDMO）滿足日益成長的需求的能力。供應鏈的脆弱性，包括對關鍵原料和一次性組件的依賴，也對生產的連續性構成風險。此外，技術轉移、智慧財產權保護和品質一致性等問題也可能成為外包夥伴關係的障礙。這些因素綜合起來會增加複雜性和成本，並可能影響市場的整體效率和擴充性。

生技藥品契約製造市場—關鍵洞察

本報告詳細分析了生物製藥契約製造市場的現狀，並指出了該行業的潛在成長機會。報告的主要發現包括：

目前全球約有 315 家公司聲稱提供生物製藥的契約製造服務，其中超過 35% 的 CMO 總部位於北美。

生物製藥的契約製造市場高度分散，尤其是大多數公司（超過 140 家）都是中型企業。
超過 50% 的生物製藥CMO 聲稱擁有 API、FDF 以及填充和包裝服務的必要能力，而絕大多數公司（約 70%）從事蛋白質/胜肽的生產。
北美（36%）和歐洲（33%）已成為生物製藥的契約製造中心。在亞太地區，中國以最多的工廠數量（49%）成為領先地區。
全球生物製藥契約製造的總產能分散在全球各地的工廠中，其中大型和超大型公司約佔總產能的 80%。
目前生物製藥契約製造市場的規模估計約為 310 億美元，預計到 2035 年將達到 639 億美元，到 2035 年的複合年成長率為 8.3%。

過去兩年，受生物製藥研發管線不斷擴大和多個後期分子藥物核准的推動，生物製藥的契約製造市場出現了策略合作激增的趨勢。
近年來，已開發國家的契約製造（CMO）優先考慮大規模投資，以增強其抗體生產能力，從而應對不斷成長的需求。

生物製藥契約製造市場

市場規模和機會分析是根據以下參數進行細分的：

提供的服務類型

原料藥（API）生產
藥物製劑（FDF）的生產

生產的生物製藥類型

抗體
番茄/胜肽
疫苗
細胞療法
基因治療
其他生物製藥

使用的表達式系統類型

哺乳動物表達系統
微生物表現系統
其他表達系統

企業規模

臨床前/臨床規模
商業規模

治療區域

腫瘤性疾病
心血管疾病
代謝性疾病
感染疾病
自體免疫疾病
神經系統疾病
遺傳性疾病
其他疾病

公司規模

小規模企業
中型公司
大型企業和巨型企業

按主要區域

北美洲
美國
加拿大
波多黎各
歐洲
德國
英國
法國
西班牙
義大利
其他歐洲國家
亞太地區
中國
韓國
日本
新加坡
亞太其他地區
世界其他地區
以色列
阿根廷
非洲

生物製藥契約製造市場：主要細分市場

哺乳動物表達系統在生物製藥契約製造市場佔主導地位。

今年，哺乳動物表達系統佔了生物製藥契約製造市場80%以上的佔有率。其主導地位源自於該系統能夠提供與人體細胞環境相似的蛋白質表現環境，確保適當的轉譯後修飾，並具有高產量、可擴展性和在多種生物製藥產品中已確立的安全性。此外，預計該細分市場在預測期內將以8.6%的複合年成長率穩定成長。

抗體療法是推動市場收入成長的主要因素，而細胞療法則顯示出快速成長的跡象。

根據我們的市場預測，抗體約佔生物製藥契約製造總收入的60%。這一顯著佔有率得益於抗體在包括腫瘤、自體免疫疾病、感染疾病和罕見疾病在內的多個治療領域的廣泛應用。展望未來，細胞療法領域預計將成為生物製藥契約製造市場中成長最快的領域，這反映出對先進治療方法的投資和創新不斷增加。

亞太地區正在推動生物製藥契約製造市場的發展。

亞太地區在生物製藥契約製造市場佔有主導地位，約佔總銷售額的40%。這一優勢主要歸功於全部區域勞動力和原料成本低廉，以及設施開發和營運所需的資本投資相對較低。

中國生物製藥契約製造市場

在亞太地區，中國佔最大的市場佔有率，這得益於其龐大的生產能力和在創新生物製藥（尤其是單株抗體和生物相似藥）研發方面的先進技術。政府主導的「健康中國2030」規劃等重點措施進一步推動了中國生物製劑產業的發展，該規劃強調加強生物製藥基礎設施建設。此外，與西方市場相比，中國的成本優勢持續吸引全球外包業務，鞏固了其在該領域的主導地位。

生物製藥契約製造市場主要公司範例

AbbVie
Agilent Technologies
Boehringer Ingelheim
Catalent
Cipla
Eurofins
Fresenius Kabi
Lonza
Novartis
Sandoz
WACKER
WuXi Biologics

第一次調查總結

本研究中提出的觀點和見解是基於與多位相關人員的討論。本研究報告包含與以下產業相關人員的詳細訪談記錄：

蘇格蘭一家中型公司的執行長
斯洛維尼亞，中小企業，執行長聯合創始人
美國某大型公司前技術長
一家中國中型公司的首席執行官
曾任美國某大型企業全球策略行銷資深總監
曾任美國某大型公司商業策略與市場洞察高階總監。
曾任美國某大型企業的全球銷售和行銷經理以及業務拓展經理。
西班牙，中小企業，業務拓展經理
行銷和銷售經理，一家德國中型公司

生物製藥契約製造市場：研究範圍

市場規模和機會分析：本報告從關鍵市場細分的角度對全球抗體合約製造市場進行了全面分析，包括[A]提供的服務類型，[B]生產的生物製藥類型，[C]使用的表達系統類型，[D]業務規模，[E]公司規模，[F]契約製造領域，以及[G]主要地區。
市場概覽：我們根據幾個相關參數對參與抗體合約生產市場的公司進行詳細評估，包括[A]成立年份，[B]公司規模，[C]總部所在地，[D]提供的服務類型，[E]契約製造的生物製藥類型，[F]業務規模，以及[G]使用的表達系統類型。
區域產能分析：這是對主要地區（包括[A]北美、[B]歐洲、[C]亞太地區和[D]世界其他地區）建立的生物製藥生產設施的全面分析。
公司簡介：詳細介紹北美、歐洲和亞太地區生物製藥契約製造市場領先服務供應商的概況。這些簡介重點關注以下幾個面向：[A] 公司概況，[B] 財務資訊（如有），[C] 服務組合，[D] 生產設施，以及 [E] 近期發展和未來展望。
案例研究- 小眾製藥領域：對該行業的關鍵促進因素進行全面評估，重點關注特定小眾產品，例如 [A]抗體藥物複合體(ADC)、[B] 雙特異性抗體、[C] 細胞療法、[D] 基因療法和 [E] 病毒載體。
案例研究- 內部生產：本案例研究詳細探討了生物製藥開發公司在決定是自行生產產品還是利用生物製藥CMO 的服務時應考慮的各種因素。
決定是自行生產還是外包的標準：我們將對各大公司實施的各種生物製藥生產舉措進行詳細調查，並闡明各個參數的趨勢，例如 [A]舉措數量，[B] 啟動年份，[C] 目的，[D] 類型，[E] 運營規模，以及 [F] 生產的生物製藥類型。
合作關係與合資企業：我們將根據相關參數對生物製藥契約製造市場的最新合作關係進行詳細分析，例如 [A] 合作年份，[B] 合作類型，[C] 生產的生物製藥類型，[D] 治療領域，[E] 最活躍的公司，以及 [F] 合作活動的地理分佈。
併購：我們將根據幾個相關參數，詳細分析該行業發生的各種併購，包括[A]協議年份，[B]交易類型，[C]公司地理位置，[D]收購類型，[E]生產的生物製藥類型，以及[F]關鍵價值促進因素。
近期業務擴張：本節詳細分析了生物製藥CMO 在相關時期開展的業務擴張工作，以及幾個相關參數的信息，包括 [A] 擴張年份，[B] 擴張目的，[C] 生產的生物製藥類型，以及 [D] 擴張設施的地點。
近期趨勢：本分析考察了生物製藥契約製造市場的最新趨勢，重點關注與[A]財務投資和[B]生物製造相關的技術進步有關的資訊。
生產能力分析：這是對生物製藥生產總設備容量的估計，揭示了基於[A]製造商規模、[B]所用表達系統的類型和[C]地區的可用生產能力分佈。
需求分析：基於各種相關參數，如[A]目標患者群體、[B]給藥頻率和[C]劑量，我們對生物製藥的年度需求進行實證估計。
總擁有成本 (TCO)：本節詳細分析了生物製藥CMO 的總擁有成本，並按公司規模進行了細分。
SWOT 分析：我們將基於全面的 SWOT 分析，研究可能影響產業發展的相關趨勢、關鍵促進因素和挑戰。
案例研究－虛擬製藥公司：關於虛擬經營模式的概念及其在整個生物製藥產業中的作用的案例研究。

章節概要
關鍵前提條件和參數
生物製藥契約製造設施概覽
區域產能分析：北美生物製藥契約製造設施
區域產能分析：歐洲生物製藥契約製造設施
區域產能分析：亞太地區生物製藥契約製造設施
區域產能分析：其他地區生物製藥契約製造設施

第9章：公司簡介

章節概要
總部位於北美的生物製劑契約製造。
- AbbVie
- Agilent Technologies
- Catalent
一家總部位於歐洲的生物製劑契約製造。
- Boehringer Ingelheim
- Eurofins
- Fresenius Kabi
- Lonza
- Novartis
- Sandoz
- WACKER
生物製藥契約製造生產商。
- Cipla
- Wuxi Biologics

第10章生物製藥的主要領域

章節概要
雙特異性抗體
抗體藥物複合體（ADC）
細胞療法
基因治療
病毒載體
質體DNA

第11章案例研究：生物相似藥外包

章節概要
生物相似藥概述
生物相似藥開發階段
生物相似藥許可的監管要求
製造營運外包的必要性
生物相似藥對全球藥品契約製造市場的影響。
生物相似藥契約製造服務供應商
生物相似藥生產外包營運面臨的挑戰

第12章案例研究：小分子藥物與大分子藥物/治療方法的比較

章節概要
小分子藥物與大分子藥物/治療方法

第13章案例研究：內部製造

第14章：製造與採購之間的決策框架

章節概要
關鍵前提條件和參數
生物製藥契約製造生產者：內部生產與外包之間的決策。
結論

第15章夥伴關係與合作

章節概要
夥伴關係模式
生物製藥契約製造生產商：夥伴關係與合作

第16章資金籌措與投資分析

章節概要
資金籌措模式
生物製藥契約製造生產商：資金籌措與投資

第17章併購

章節概要
併購類型
生物製藥契約製造生產商：併購

第18章近期擴張

章節概要
擴充類型
生物製藥契約製造：近期業務擴張

第19章：主要製藥公司的舉措

章節概要
生物製藥契約製造：大型製藥公司
生物製藥契約製造：大型製藥公司的舉措

第20章能力分析

第21章需求分析

第22章總擁有成本

第23章 SWOT分析

第24章：全球生物製藥契約製造市場

第25章：生物製藥契約製造市場（依服務類型分類）

第26章：生物製藥契約製造市場（依生產的生物製藥類型分類）

第27章：生物製藥的契約製造市場（依表達系統類型分類）

第28章：生物製藥契約製造市場（依企業規模分類）

第29章：生物製藥契約製造市場（依公司規模分類）

第30章：生物製藥契約製造市場（依治療領域分類）

第31章：生物製藥契約製造市場（依主要地區分類）

第32章：生物製藥契約製造市場：北美

第33章：生物製藥契約製造市場：歐洲

第34章：生物製藥契約製造市場：亞太地區

第35章：生物製藥契約製造市場：其他地區

第36章案例研究：虛擬製藥公司

第37章：生物製藥CMO市場的未來展望

第38章結論

第39章：高階主管洞察

第40章附錄一：表格形式數據

第41章附錄二：公司與組織列表

簡介目錄圖表

Product Code: RA100465

Biologics Contract Manufacturing Market: Overview

As per Roots Analysis, the global biologics contract manufacturing market is estimated to grow from USD 31.0 billion in the current year to USD 63.9 billion by 2035, at a CAGR of 8.3% during the forecast period, till 2035.

Biologics Contract Manufacturing Market: Growth and Trends

Biopharmaceuticals are therapeutic products derived from living organisms or semi-synthesized from biological sources. Owing to their complex macromolecular structures typically exceeding 1,000 Daltons, these products often fall beyond the scope of conventional chemical synthesis, prompting industry stakeholders to invest in advanced biotechnological platforms to enable scalable and efficient manufacturing.

The increasing prevalence of chronic diseases, coupled with a growing shift toward advanced therapeutic modalities, has significantly accelerated demand for biologics development. In response, a large number of developers are outsourcing manufacturing operations to specialized third-party service providers to address rising capacity requirements and enhance operational efficiency. Notably, such outsourcing strategies enable access to expanded production capabilities, technical expertise, and diversified product portfolios. Among outsourced activities, analytical testing, toxicity assessment, and fill-finish operations represent key service segments.

Additionally, demand for biopharmaceutical and pharmaceutical contract manufacturing, along with downstream process development, continues to rise. To capitalize on these opportunities, smaller service providers are actively expanding their technical capabilities and forming strategic partnerships with contract development and manufacturing organizations (CDMOs) to broaden their service offerings. As outsourcing gains wider acceptance as a strategic and cost-effective business model, the global biologics contract manufacturing market is poised for robust growth over the forecast period.

Growth Drivers: Strategic Enablers of Market Expansion

The biologics contract manufacturing market is propelled by ongoing advancements in advanced bioprocessing technologies such as single-use bioreactors, continuous perfusion systems, and AI-driven automation without incurring significant capital expenditure on in-house infrastructure. Contract manufacturing organizations (CMOs) make substantial investments in next-generation facilities, offering enhanced technical capabilities that improve production yields, minimize contamination risks, and support rapid scalability.

In addition, these service providers deliver high levels of operational flexibility, allowing companies to efficiently scale manufacturing across different volumes while addressing dynamic market demands and unforeseen challenges. Outsourcing manufacturing activities also drives significant cost efficiencies by reducing overhead and operational burdens. This, in turn, enables biopharmaceutical companies to allocate greater resources toward core competencies, particularly research and development. Overall, the model supports both innovation and cost optimization, strengthening the industry's value proposition.

Market Challenges: Critical Barriers Impeding Progress

The biologics contract manufacturing market faces several structural and operational challenges that may constrain its growth trajectory. A key concern is the high complexity of biologics production, which requires stringent process control, specialized infrastructure, and skilled expertise, thereby increasing the risk of batch failures and deviations. Additionally, regulatory compliance across multiple jurisdictions remains a significant hurdle, often leading to delays in approvals and increased operational costs.

Capacity constraints and long lead times, particularly for large-scale commercial manufacturing, further limit the ability of contract development and manufacturing organizations (CDMOs) to meet rising demand. Supply chain vulnerabilities, including dependence on critical raw materials and single-use components, also pose risks to production continuity. Moreover, issues related to technology transfer, intellectual property protection, and quality consistency can create barriers in outsourcing partnerships. Collectively, these factors add layers of complexity and cost, potentially impacting the overall efficiency and scalability of the market.

Biologics Contract Manufacturing Market: Key Insights

The report delves into the current state of the biologics contract manufacturing market and identifies potential growth opportunities within industry. Some key findings from the report include:

The current market landscape features the presence of ~315 players that claim to offer contract manufacturing services for biopharmaceuticals across the world; of these, >35% of CMOs are headquartered in North America.

Biologics Contract Manufacturing Market - IMG1

The biopharmaceutical contract manufacturing market is highly fragmented; notably, majority (>140) of the players are mid-sized companies.
Over 50% of the biopharmaceutical CMOs claim to possess the necessary capabilities in API, FDF, and fill-finish services; majority (~70%) of the players are engaged in the manufacturing of protein / peptides.
North America (36%) and Europe (33%) emerged as the contract manufacturing hubs for biologics; within Asia-Pacific, China emerged as the prominent region, having the highest number of facilities (49%).
The global installed biopharmaceutical contract manufacturing capacity is distributed across different facilities worldwide; large and very large players account for around 80% of the total capacity.
The current biopharmaceutical contract manufacturing market size is estimated to be around USD 31.0 billion, and this value is projected to reach USD 63.9 billion by 2035, growing at a CAGR of 8.3% through 2035

Since the past two years, the biopharmaceutical contract manufacturing market has seen a surge in strategic partnerships driven by the expanding biologics pipeline and approvals of several late-stage molecules.
Over the recent past, CMOs in developed economies have prioritized large-scale investments to enhance antibody production capacities amid escalating demand.

Biologics Contract Manufacturing Market

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Service Offered

Drug Substance (API) Manufacturing
Drug Product (FDF) Manufacturing

Type of Biologic Manufactured

Antibodies
Proteins / Peptides
Vaccines
Cell Therapies
Gene Therapies
Other Biologics

Type of Expression System Used

Mammalian Expression Systems
Microbial Expression Systems
Other Expression Systems

Scale of Operation

Preclinical / Clinical Scale
Commercial Scale

Therapeutic Area

Oncological Disorders
Cardiovascular Disorders
Metabolic Disorders
Infectious Diseases
Autoimmune Disorders
Neurological Disorders
Genetic Disorders
Other Disorders

Company Size

Small Companies
Mid-sized Companies
Large and Very Large Companies

By Key Geographical Regions

North America
US
Canada
Puerto Rico
Europe
Germany
UK
France
Spain
Italy
Rest of Europe
Asia-Pacific
China
South Korea
Japan
Singapore
Rest of the Asia-Pacific
Rest of the World
Israel
Argentina
Africa

Biologics Contract Manufacturing Market: Key Segments

Mammalian Expression Systems Dominate Outsourced Biologics Manufacturing

In the current year, mammalian expression systems account for over 80% of the total biologics contract manufacturing market share. This dominance is attributed to their ability to provide a human-like cellular environment for protein expression, ensuring appropriate post-translational modifications, along with high production yields, scalability, and an established safety profile across a wide range of biopharmaceutical products. Furthermore, this segment is projected to witness robust expansion, growing at a compound annual growth rate (CAGR) of 8.6% over the forecast period.

Antibodies Segment Leads Market Revenue; Cell Therapies Poised for Accelerated Growth

Based on our market forecast, antibodies represent approximately 60% of the overall biologics contract manufacturing revenue. This significant share is driven by their widespread application across multiple therapeutic areas, including oncology, autoimmune diseases, infectious disorders, and rare conditions. Looking ahead, the cell therapies segment is expected to register the fastest growth within the biologics contract manufacturing market, reflecting increasing investment and innovation in advanced therapeutic modalities.

Asia-Pacific Leads the Biologics Contract Manufacturing Market

The Asia-Pacific region holds a leading position in the biologics contract manufacturing market, accounting for approximately 40% of the overall revenue share. This dominance is primarily driven by the availability of cost-effective labor and raw materials, as well as comparatively lower capital expenditure associated with facility development and operations across the region.

China Biologics Contract Manufacturing Market

Within Asia-Pacific, China represents the largest market, underpinned by its substantial manufacturing capacity and advanced technical expertise in the development of innovative biologics, particularly monoclonal antibodies and biosimilars. Growth in the country is further supported by significant government initiatives, such as the Healthy China 2030 program, which emphasizes strengthening biopharmaceutical infrastructure. Additionally, China's cost advantages in comparison to Western markets continue to attract global outsourcing activities, reinforcing its leadership in the domain.

Example Players in the Biologics Contract Manufacturing Market

AbbVie
Agilent Technologies
Boehringer Ingelheim
Catalent
Cipla
Eurofins
Fresenius Kabi
Lonza
Novartis
Sandoz
WACKER
WuXi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, Mid-Sized Company, Scotland
Chief Executive Officer and Co-Founder, Small Company, Slovenia
Former Chief Technical Officer, Large Company, US
President, Mid-Sized Company, China
Former Senior Director of Global Strategic Marketing, Large Company, US
Former Senior Director of Commercial Strategy and Market Insights, Large Company, US
Former Global Head of Sales and Marketing and Head of Business Development, Large Company, US
Business Development Manager, Small Company, Spain
Manager Marketing and Sales, Mid-Sized Company, Germany

Biologics Contract Manufacturing Market: Research Coverage

Market Sizing and Opportunity Analysis: The report features a thorough analysis of the global antibody contract manufacturing market, in terms of the key market segments, including [A] type of service(s) offered, [B] type of biologic manufactured, [C] type of expression system used, [D] scale of operation, [E] company size, [F] therapeutic area and [G] key geographical regions.
Market Landscape: An in-depth assessment of the companies involved in antibody contract manufacturing market, based on several relevant parameters, such as [A] year of establishment, [B] company size, [C] location of headquarters, [D] type of service offered, [E] type of biologic manufactured, [F] scale of operation, and [G] type of expression systems used.
Regional Capability Analysis: A comprehensive analysis of biopharmaceutical manufacturing facilities established across the key geographical regions, such as [A] North America [B] Europe [C] Asia-Pacific, and [D] rest of the world.
Company Profiles: Detailed profiles of key service providers across North America, Europe and Asia-Pacific engaged in the biologics contract manufacturing market, focused on parameters such as [A] company overview, [B] financial information (if available), [C] service portfolio, [D] manufacturing facilities and [E] recent developments and an informed future outlook.
Case Study - Niche Pharmaceutical Sectors: A comprehensive evaluation of the primary enablers within this industry, highlighting specific niche products such as [A] antibody-drug conjugates (ADCs), [B] bispecific antibodies, [C] cell therapies, [D] gene therapies, and [E] viral vectors.
Case Study - In-house Manufacturing: A detailed review of various factors that need to be taken into consideration by biopharmaceutical developers while deciding whether to manufacture their respective products in-house or engage the services of a biologics CMO.
Make Versus Buy Framework: An elaborate study of the various biopharmaceutical-focused manufacturing initiatives undertaken by top big pharma players, highlighting trends across various parameters, such as [A] number of initiatives, [B] year of initiative, [C] purpose of initiative, [D] type of initiative, [E] scale of operation and [F] type of biologic manufactured.
Partnerships and Collaborations: An in-depth analysis of the recent collaborations within the biologics contract manufacturing market, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] type of biologic manufactured, [D] therapeutic area, [E] most active players and [F] regional distribution of partnership activity that have taken place in this industry.
Mergers and Acquisitions: A detailed analysis of the various mergers and acquisitions that have taken place within this industry, based on several relevant parameters, [A] such as year of agreement, [B] type of deal, [C] geographical location of companies, [D] type of acquisition, [E] type of biologic manufactured and [F] key value drivers.
Recent Expansions: A detailed analysis of expansion initiatives undertaken by biologics CMO, during the period along with information on several relevant parameters, such as [A] year of expansion, [B] purpose of expansion, [C] type of biologic manufactured and [D] location of expanded facility.
Recent Developments: An analysis of the recent developments within the biologics contract manufacturing market, highlighting information on the [A] funding investments made and [B] information on the technology advancements related to biomanufacturing.
Capacity Analysis: An estimate of the overall installed capacity for the manufacturing of biopharmaceuticals, highlighting the distribution of the available capacity, based on [A] size of manufacturer, [B]type of expression system used and [C] geography.
Demand Analysis: An informed estimate of the annual demand for biologics, based on various relevant parameters, such as [A] target patient population, [B] dosing frequency and [C] dose strength.
Total Cost of Ownership: A company size-wise, detailed analysis of the total cost of ownership for biologics CMO.
SWOT Analysis: A discussion on affiliated trends, key drivers and challenges, under an elaborate SWOT analysis, which are likely to impact the industry's evolution.
Case Study - Virtual Pharmaceutical Companies: A case study on the virtual business model concept, along with its role in the overall biopharmaceutical industry.

Key Questions Answered in this Report

Which are the leading companies in the biologics contract manufacturing market?
Which region dominates the biologics contract manufacturing market?
What are the key trends observed in the biologics contract manufacturing market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by biologics contract manufacturers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Biopharmaceuticals
6.3. Expression Systems for Biopharmaceuticals
- 6.3.1. Insect Expression Systems
- 6.3.2. Mammalian Expression Systems
- 6.3.3. Microbial Expression Systems
  - 6.3.3.1. Bacterial Expression Systems
  - 6.3.3.2. Fungal Expression Systems
  - 6.3.3.3. Yeast Expression Systems
- 6.3.4. Plant Expression Systems
- 6.3.5. Mammalian versus Microbial Expression Systems
6.4. Manufacturing Process of Biopharmaceuticals
- 6.4.1. Upstream Processing
- 6.4.2. Fermentation
- 6.4.3. Downstream Processing
6.5. Overview of Contract Manufacturing
6.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
- 6.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
- 6.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
- 6.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
6.7. Key Considerations While Selecting a Contract Manufacturing Partner
6.8. Future Perspectives

7. MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
- 7.2.1. Analysis by Year of Establishment
- 7.2.2. Analysis by Company Size
- 7.2.3. Analysis by Location of Headquarters
- 7.2.4. Analysis by Company Size and Location of Headquarters
7.3. Biopharmaceutical Contract Manufacturers: Analysis of Key Players
- 7.3.1. Analysis by Compliance
- 7.3.2. Analysis by Type of Service Offered
- 7.3.3. Analysis by Type of Biologic Manufactured
- 7.3.4. Analysis by Scale of Operation
- 7.3.5. Analysis by Type of Expression System Used
- 7.3.6. Analysis by Type of Primary Container Offered

8. REGIONAL CAPABILITY ANALYSIS

8.1. Chapter Overview
8.2. Key Assumptions and Parameters
8.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
- 8.3.1. Analysis by Type of Service Offered
- 8.3.2. Analysis by Scale of Operation
8.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
8.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
8.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
8.7. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World

9. COMPANY PROFILES

9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturers headquartered in North America
- 9.2.1. AbbVie
  - 9.2.1.1. Company Overview
  - 9.2.1.2. Service Portfolio
- 9.2.2. Agilent Technologies
- 9.2.3. Catalent
9.3. Biopharmaceutical Contract Manufacturers headquartered in Europe
- 9.3.1. Boehringer Ingelheim
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Service Portfolio
- 9.3.2. Eurofins
- 9.3.3. Fresenius Kabi
- 9.3.4. Lonza
- 9.3.5. Novartis
- 9.3.6. Sandoz
- 9.3.7. WACKER
9.4. Biopharmaceutical Contract Manufacturers headquartered in Asia-Pacific
- 9.4.1. Cipla
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Service Portfolio
- 9.4.2. Wuxi Biologics

10. PROMINENT BIOPHARMACEUTICAL SECTORS

10.1. Chapter Overview
10.2. Bispecific Antibodies
- 10.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
- 10.2.2. Bispecific Antibodies Market: Pipeline Analysis
  - 10.2.2.1. Analysis by Phase of Development
  - 10.2.2.2. Analysis by Target Indication
- 10.2.3. Preclinical Bispecific Antibody Therapeutics: Overall Market Landscape
  - 10.2.3.1. Analysis by Stage of Development
  - 10.2.3.2. Key Considerations for Manufacturing and Associated Challenges
- 10.2.4. Role of CMOs in Offering Services for Bispecific Antibodies
10.3. Antibody Drug Conjugates (ADCs)
- 10.3.1. Components of ADCs
  - 10.3.1.1. Antibody
  - 10.3.1.2. Cytotoxin
  - 10.3.1.3. Linker
- 10.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
  - 10.3.2.1. Analysis by Stage of Development
  - 10.3.2.2. Analysis by Target Indication
  - 10.3.2.3. Most Active Player: Analysis by Number of Therapies
- 10.3.3. Antibody Drug Conjugate Developers
- 10.3.4. Manufacturing Process
- 10.3.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
- 10.3.6. Role of CMOs in Offering Services for ADCs
10.4. Cell Therapies
- 10.4.1. Cell Therapies: Overall Market Landscape
- 10.4.2. Overview of Cell Therapy Manufacturing
- 10.4.3. Cell Therapy Manufacturing Models
  - 10.4.3.1. Centralized Manufacturing
  - 10.4.3.2. Decentralized Manufacturing
- 10.4.4. Scalability of Cell Therapy Manufacturing Processes
  - 10.4.4.1. Scale-up
  - 10.4.4.2. Scale-out
- 10.4.5. Types of Cell Therapy Manufacturers
- 10.4.6. Key Challenges for Manufacturing Cell Therapies
- 10.4.7. Key Factors Influencing Cell Therapy Manufacturing
  - 10.4.7.1. Cell Characterization
  - 10.4.7.2. Cost of Goods
- 10.4.8. Automation of Cell Therapy Manufacturing
- 10.4.9. Cell Therapies: Pipeline Analysis
  - 10.4.9.1. Analysis by Type of Cell Manufactured
  - 10.4.9.2. Analysis by Type of Immune Cell Offered
10.5. Gene Therapies
- 10.5.1. Gene Therapies: Pipeline Analysis
  - 10.5.1.1. Analysis by Stage of Development
  - 10.5.1.2. Analysis by Type of Vector Used
  - 10.5.1.3. Analysis by Therapeutic Area
- 10.5.2. Role of CMOs in Offering Services for Cell / Gene Therapies
10.6. Viral Vectors
- 10.6.1. Viral Vectors: Pipeline Analysis
  - 10.6.1.1. Analysis by Location of Vector Manufacturing Facility
  - 10.6.1.2. Analysis by Type of Viral Vector Manufactured
10.7. Plasmid DNA
- 10.7.1. Plasmid DNA: Pipeline Analysis
  - 10.7.1.1. Analysis by Location of Manufacturing Facilities
- 10.7.2. Role of CMOs in Offering Services for Plasmid DNA / Viral Vectors

11. CASE STUDY: OUTSOURCING OF BIOSIMILARS

11.1. Chapter Overview
11.2. Overview of Biosimilars
11.3. Development Stages of Biosimilars
11.4. Regulatory Requirements for Licensing of Biosimilars
11.5. Need for Outsourcing Manufacturing Operations
11.6. Impact of Biosimilars on the Global Contract Manufacturing Market
- 11.6.1. Biosimilars: Historical Trend of FDA Approvals
11.7. Biosimilars Contract Manufacturing Service Providers
11.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

12. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

12.1. Chapter Overview
12.2. Small Molecule and Large Molecule Drugs / Therapies
- 12.2.1. Comparison of General Characteristics
- 12.2.2. Comparison of Key Specifications
- 12.2.3. Comparison of Manufacturing Process
- 12.2.4. Comparison of Key Manufacturing Challenges

13. CASE STUDY: IN-HOUSE MANUFACTURING

13.1. Chapter Overview
13.2. In-House Manufacturing
- 13.2.1. Benefits Associated with In-House Manufacturing
- 13.2.2. Risks Associated with In-House Manufacturing
13.3. Outsourcing Trends in the Biopharmaceutical Industry
- 13.3.1. Types of Outsourcing Partners
13.4. Manufacturing Approaches Used for Approved Biologics
13.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

14.1. Chapter Overview
14.2. Key Assumptions and Parameters
14.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
- 14.3.1. Scenario 1
- 14.3.2. Scenario 2
- 14.3.3. Scenario 3
- 14.3.4. Scenario 4
14.4. Conclusion

15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview
15.2. Partnership Models
15.3. Biopharmaceutical Contract Manufacturers: Partnerships and Collaborations
- 15.3.1. Cumulative Trend of Partnerships
- 15.3.2. Analysis by Type of Partnership
- 15.3.3. Analysis by Quarter and Type of Partnership
- 15.3.4. Analysis by Type of Biologic Manufactured
- 15.3.5. Analysis by Scale of Operation
- 15.3.6. Analysis by Therapeutic Area
- 15.3.7. Most Active Players: Analysis by Number of Partnerships
- 15.3.8. Analysis by Geography
  - 15.3.8.1. Local and International Agreements
  - 15.3.8.2. Intracontinental and Intercontinental Agreements

16. FUNDING AND INVESTMENTS ANALYSIS

16.1. Chapter Overview
16.2. Funding Models
16.3. Biopharmaceutical Contract Manufacturers: Funding and Investments
- 16.3.1. Cumulative Trend of Funding
- 16.3.2. Cumulative Trend of Amount Invested
- 16.3.3. Analysis of Instances by Type of Funding
- 16.3.4. Analysis by Quarter and Type of Funding
- 16.3.5. Analysis of Amount Invested by Type of Funding
- 16.3.6. Analysis of Amount Invested by Quarter and Type of Funding
- 16.3.7. Analysis by Geography
- 16.3.8. Most Active Players: Analysis by Number of Funding Instances
- 16.3.9. Most Active Players: Analysis by Amount Invested

17. MERGERS AND ACQUISITIONS

17.1. Chapter Overview
17.2. Types of Mergers and Acquisitions
17.3. Biopharmaceutical Contract Manufacturers: Mergers and Acquisitions
- 17.3.1. Cumulative Trend of Mergers and Acquisitions
- 17.3.2. Analysis by Type of Agreement
- 17.3.3. Analysis by Geography
  - 17.3.3.1. Local and International Agreements
  - 17.3.3.2. Intracontinental and Intercontinental Agreements
- 17.3.4. Most Active Players: Analysis by Number of Agreements
- 17.3.5. Ownership Change Matrix
- 17.3.6. Analysis by Key Value Drivers

18. RECENT EXPANSIONS

18.1. Chapter Overview
18.2. Type of Expansions
18.3. Biopharmaceutical Contract Manufacturers: Recent Expansions
- 18.3.1. Cumulative Trend of Expansions
- 18.3.2. Analysis by Type of Expansion
- 18.3.3. Analysis by Quarter and Type of Expansion
- 18.3.4. Analysis by Location of Facility (Region)
- 18.3.5. Analysis by Location of Facility (Country)
- 18.3.6. Analysis by Type of Expansion and Location of Facility (Region)
- 18.3.7. Analysis of Amount Invested by Year of Expansion
- 18.3.8. Analysis of Amount Invested by Type of Expansion
- 18.3.9. Most Active Players: Analysis by Number of Expansions
- 18.3.10. Most Active Players: Analysis by Amount Invested

19. BIG PHARMA INITIATIVES

19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturers: Big Pharma Players
19.3. Biopharmaceutical Contract Manufacturers: Initiatives Undertaken by Big Pharma Players
- 19.3.1. Cumulative Trend of Big Pharma Initiatives
- 19.3.2. Analysis by Type of Initiative
- 19.3.3. Analysis by Quarter and Type of Initiative
- 19.3.4. Analysis of Big Pharma Players by Number of Initiatives
- 19.3.5. Analysis by Type of Partnership
- 19.3.6. Analysis of Big Pharma Players by Number of Partnerships
- 19.3.7. Analysis by Type of Acquisition
- 19.3.8. Analysis of Big Pharma Players by Number of Mergers and Acquisitions
- 19.3.9. Analysis of Big Pharma Players by Number of Expansions
- 19.3.10. Big Pharma Initiatives Summary

20. CAPACITY ANALYSIS

20.1. Chapter Overview
20.2. Key Assumptions and Methodology
20.3. Biopharmaceutical Contract Manufacturing: Global Installed Capacity
- 20.3.1. Analysis by Company Size
- 20.3.2. Analysis by Type of Expression System Used
- 20.3.3. Analysis by Geography
  - 20.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
  - 20.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
  - 20.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  - 20.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
20.4. Concluding Remarks

21. DEMAND ANALYSIS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Global Demand for Biopharmaceutical Contract Manufacturing
21.4. Global Demand for Biopharmaceutical Contract Manufacturing: Analysis by Scale of Operation
21.5. Global Demand for Emerging Novel Biologics
- 21.5.1. Global Demand for ADC Therapeutics
- 21.5.2. Global Demand for Cell Therapy Manufacturing

22. TOTAL COST OF OWNERSHIP

22.1. Chapter Overview
22.2. Key Parameters
22.3. Assumptions and Methodology
22.4. Total Cost of Ownership (Sample Dataset)
22.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
- 22.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
- 22.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
22.6. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
- 22.6.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
- 22.6.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20

23. SWOT ANALYSIS

23.1. Chapter Overview
23.2. Strengths
23.3. Weaknesses
23.4. Opportunities
23.5. Threats
23.6. Comparison of SWOT Factors
23.7. Conclusion

24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET

24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biologics Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 24.3.1. Roots Analysis Perspective on Market Growth
- 24.3.2. Scenario Analysis
  - 24.3.2.1. Conservative Scenario
  - 24.3.2.2. Optimistic Scenario
24.4. Key Market Segmentations

25. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biologics Contract Manufacturing Market: Distribution by Type of Service Offered
- 25.3.1. Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 25.3.2. Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biologics Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
- 26.3.1. Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 26.3.2. Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 26.3.3. Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 26.3.4. Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 26.3.5. Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 26.3.6. Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation

27. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biologics Contract Manufacturing Market: Distribution by Type of Expression System Used
- 27.3.1. Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 27.3.2. Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 27.3.3. Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biologics Contract Manufacturing Market: Distribution by Scale of Operation
- 28.3.1. Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 28.3.2. Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biologics Contract Manufacturing Market: Distribution by Company Size
- 29.3.1. Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 29.3.2. Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 29.3.3. Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY THERAPEUTIC AREA

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
- 30.3.1. Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.2. Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.3. Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.4. Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.5. Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.6. Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.7. Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 30.3.8. Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY KEY GEOGRAPHICAL REGIONS

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Biologics Contract Manufacturing Market: Distribution by Key Geographical Regions
- 31.3.1. North America: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.1.1. US: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.1.2. Canada: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.1.3. Puerto Rico: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 31.3.2. Europe: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.1. Germany: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.2. UK: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.3. France: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.4. Spain: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.5. Italy: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.2.6. Rest of Europe: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 31.3.3. Asia-Pacific: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.3.1. China: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.3.2. South Korea: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.3.3. Japan: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.3.4. Singapore: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.3.5. Rest of Asia-Pacific: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 31.3.4. Rest of the World: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.4.1. Israel: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.4.2. Argentina: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
  - 31.3.4.3. Africa: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
31.4. Market Dynamics Assessment
- 31.4.1. Market Movement Analysis
- 31.4.2. Penetration Growth (P-G) Matrix
31.5. Data Triangulation and Validation

32. BIOLOGICS CONTRACT MANUFACTURING MARKET: NORTH AMERICA

32.1. Biologics Contract Manufacturing Market in North America: Distribution by Type of Service Offered
- 32.1.1. Biologics Contract Manufacturing Market in North America for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.1.2. Biologics Contract Manufacturing Market in North America for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.2. Biologics Contract Manufacturing Market in North America: Distribution by Type of Biologic Manufactured
- 32.2.1. Biologics Contract Manufacturing Market in North America for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.2. Biologics Contract Manufacturing Market in North America for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.3. Biologics Contract Manufacturing Market in North America for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.4. Biologics Contract Manufacturing Market in North America for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.5. Biologics Contract Manufacturing Market in North America for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.2.6. Biologics Contract Manufacturing Market in North America for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.3. Biologics Contract Manufacturing Market in North America: Distribution by Type of Expression System Used
- 32.3.1. Biologics Contract Manufacturing Market in North America for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.3.2. Biologics Contract Manufacturing Market in North America for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.3.3. Biologics Contract Manufacturing Market in North America for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.4. Biologics Contract Manufacturing Market: Distribution by Scale of Operation
- 32.4.1. Biologics Contract Manufacturing Market in North America for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.4.2. Biologics Contract Manufacturing Market in North America for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.5. Biologics Contract Manufacturing Market: Distribution by Company Size
- 32.5.1. Biologics Contract Manufacturing Market in North America for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.5.2. Biologics Contract Manufacturing Market in North America for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.5.3. Biologics Contract Manufacturing Market in North America for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
32.6. Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
- 32.6.1. Biologics Contract Manufacturing Market in North America for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.2. Biologics Contract Manufacturing Market in North America for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.3. Biologics Contract Manufacturing Market in North America for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.4. Biologics Contract Manufacturing Market in North America for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.5. Biologics Contract Manufacturing Market in North America for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.6. Biologics Contract Manufacturing Market in North America for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.7. Biologics Contract Manufacturing Market in North America for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 32.6.8. Biologics Contract Manufacturing Market in North America for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)

33. BIOLOGICS CONTRACT MANUFACTURING MARKET: EUROPE

33.1. Biologics Contract Manufacturing Market in Europe: Distribution by Type of Service Offered
- 33.1.1. Biologics Contract Manufacturing Market in Europe for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.1.2. Biologics Contract Manufacturing Market in Europe for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.2. Biologics Contract Manufacturing Market in Europe: Distribution by Type of Biologic Manufactured
- 33.2.1. Biologics Contract Manufacturing Market in Europe for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.2. Biologics Contract Manufacturing Market in Europe for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.3. Biologics Contract Manufacturing Market in Europe for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.4. Biologics Contract Manufacturing Market in Europe for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.5. Biologics Contract Manufacturing Market in Europe for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.2.6. Biologics Contract Manufacturing Market in Europe for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.3. Biologics Contract Manufacturing Market in Europe: Distribution by Type of Expression System Used
- 33.3.1. Biologics Contract Manufacturing Market in Europe for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.3.2. Biologics Contract Manufacturing Market in Europe for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.3.3. Biologics Contract Manufacturing Market in Europe for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.4. Biologics Contract Manufacturing Market: Distribution by Scale of Operation
- 33.4.1. Biologics Contract Manufacturing Market in Europe for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.4.2. Biologics Contract Manufacturing Market in Europe for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.5. Biologics Contract Manufacturing Market: Distribution by Company Size
- 33.5.1. Biologics Contract Manufacturing Market in Europe for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.5.2. Biologics Contract Manufacturing Market in Europe for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.5.3. Biologics Contract Manufacturing Market in Europe for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
33.6. Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
- 33.6.1. Biologics Contract Manufacturing Market in Europe for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.2. Biologics Contract Manufacturing Market in Europe for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.3. Biologics Contract Manufacturing Market in Europe for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.4. Biologics Contract Manufacturing Market in Europe for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.5. Biologics Contract Manufacturing Market in Europe for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.6. Biologics Contract Manufacturing Market in Europe for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.7. Biologics Contract Manufacturing Market in Europe for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 33.6.8. Biologics Contract Manufacturing Market in Europe for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)

34. BIOLOGICS CONTRACT MANUFACTURING MARKET: ASIA-PACIFIC

34.1. Biologics Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Service Offered
- 34.1.1. Biologics Contract Manufacturing Market in Asia-Pacific for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.1.2. Biologics Contract Manufacturing Market in Asia-Pacific for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.2. Biologics Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Biologic Manufactured
- 34.2.1. Biologics Contract Manufacturing Market in Asia-Pacific for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.2. Biologics Contract Manufacturing Market in Asia-Pacific for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.3. Biologics Contract Manufacturing Market in Asia-Pacific for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.4. Biologics Contract Manufacturing Market in Asia-Pacific for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.5. Biologics Contract Manufacturing Market in Asia-Pacific for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.2.6. Biologics Contract Manufacturing Market in Asia-Pacific for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.3. Biologics Contract Manufacturing Market in Asia-Pacific: Distribution by Type of Expression System Used
- 34.3.1. Biologics Contract Manufacturing Market in Asia-Pacific for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.3.2. Biologics Contract Manufacturing Market in Asia-Pacific for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.3.3. Biologics Contract Manufacturing Market in Asia-Pacific for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.4. Biologics Contract Manufacturing Market: Distribution by Scale of Operation
- 34.4.1. Biologics Contract Manufacturing Market in Asia-Pacific for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.4.2. Biologics Contract Manufacturing Market in Asia-Pacific for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.5. Biologics Contract Manufacturing Market: Distribution by Company Size
- 34.5.1. Biologics Contract Manufacturing Market in Asia-Pacific for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.5.2. Biologics Contract Manufacturing Market in Asia-Pacific for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.5.3. Biologics Contract Manufacturing Market in Asia-Pacific for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
34.6. Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
- 34.6.1. Biologics Contract Manufacturing Market in Asia-Pacific for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.2. Biologics Contract Manufacturing Market in Asia-Pacific for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.3. Biologics Contract Manufacturing Market in Asia-Pacific for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.4. Biologics Contract Manufacturing Market in Asia-Pacific for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.5. Biologics Contract Manufacturing Market in Asia-Pacific for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.6. Biologics Contract Manufacturing Market in Asia-Pacific for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.7. Biologics Contract Manufacturing Market in Asia-Pacific for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 34.6.8. Biologics Contract Manufacturing Market in Asia-Pacific for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)

35. BIOLOGICS CONTRACT MANUFACTURING MARKET: REST OF THE WORLD

35.1. Biologics Contract Manufacturing Market in Rest of the world: Distribution by Type of Service Offered
- 35.1.1. Biologics Contract Manufacturing Market in Rest of the world for Drug Substance (API) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.1.2. Biologics Contract Manufacturing Market in Rest of the world for Drug Product (FDF) Manufacturing: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.2. Biologics Contract Manufacturing Market in Rest of the world: Distribution by Type of Biologic Manufactured
- 35.2.1. Biologics Contract Manufacturing Market in Rest of the world for Antibodies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.2.2. Biologics Contract Manufacturing Market in Rest of the world for Proteins / Peptides: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.2.3. Biologics Contract Manufacturing Market in Rest of the world for Vaccines: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.2.4. Biologics Contract Manufacturing Market in Rest of the world for Cell Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.2.5. Biologics Contract Manufacturing Market in Rest of the world for Gene Therapies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.2.6. Biologics Contract Manufacturing Market in Rest of the world for Other Biologics: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.3. Biologics Contract Manufacturing Market in Rest of the world: Distribution by Type of Expression System Used
- 35.3.1. Biologics Contract Manufacturing Market in Rest of the world for Mammalian Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.3.2. Biologics Contract Manufacturing Market in Rest of the world for Microbial Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.3.3. Biologics Contract Manufacturing Market in Rest of the world for Other Expression Systems: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.4. Biologics Contract Manufacturing Market: Distribution by Scale of Operation
- 35.4.1. Biologics Contract Manufacturing Market in Rest of the world for Preclinical / Clinical Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.4.2. Biologics Contract Manufacturing Market in Rest of the world for Commercial Scale: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.5. Biologics Contract Manufacturing Market: Distribution by Company Size
- 35.5.1. Biologics Contract Manufacturing Market in Rest of the world for Small Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.5.2. Biologics Contract Manufacturing Market in Rest of the world for Mid-sized Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.5.3. Biologics Contract Manufacturing Market in Rest of the world for Large and Very Large Companies: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
35.6. Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
- 35.6.1. Biologics Contract Manufacturing Market in Rest of the world for Oncological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.2. Biologics Contract Manufacturing Market in Rest of the world for Cardiovascular Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.3. Biologics Contract Manufacturing Market in Rest of the world for Metabolic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.4. Biologics Contract Manufacturing Market in Rest of the world for Infectious Diseases: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.5. Biologics Contract Manufacturing Market in Rest of the world for Autoimmune Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.6. Biologics Contract Manufacturing Market in Rest of the world for Neurological Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.7. Biologics Contract Manufacturing Market in Rest of the world for Genetic Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)
- 35.6.8. Biologics Contract Manufacturing Market in Rest of the world for Other Disorders: Historical Trends (since 2022) and Forecasted Estimates (till 2035)

36. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES

36.1. Chapter Overview
36.2. Historical Evolution of the Virtual Business Model
36.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
36.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
36.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers

37. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

37.1. Chapter Overview
37.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
37.3. Shift from One-time Contracts to Strategic Partnerships
37.4. Integration / Adoption of New and Innovative Technologies
- 37.4.1. Single-use Bioreactors
- 37.4.2. Novel Bioprocess Techniques
- 37.4.3. Bioprocess Automation
37.5. Focus on Prominent Therapeutic Areas
37.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
37.7. Capability Expansion by CMOs to become One-Stop-Shops
37.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
37.9. Increase in Financial Inflow and Outsourcing Budgets
37.10. Challenges Faced by Sponsors and Service Providers
- 37.10.1. Concerns Related to Single-use Systems
- 37.10.2. Issues Related to Capacity Fluctuations
37.11. Concluding Remarks

38. CONCLUSION

39. EXECUTIVE INSIGHTS

39.1. Chapter Overview
39.2. RoslinCT
- 39.2.1. Company Snapshot
- 39.2.2. Interview Transcript: Chief Executive Officer
39.3. JAFRAL Biosolutions
- 39.3.1. Company Snapshot
- 39.3.2. Interview Transcript: Chief Executive Officer and Co-Founder
39.4. Discovery Life Sciences
- 39.4.1. Company Snapshot
- 39.4.2. Interview Transcript: Former Chief Technical Officer, Cell and Gene Therapy
39.5. Bioworkshops
- 39.5.1. Company Snapshot
- 39.5.2. Interview Transcript: President and Chief Operating Officer
39.6. Aldevron
- 39.6.1. Company Snapshot
- 39.6.2. Interview Transcript: Former Senior Director of Global Strategic Marketing
39.7. Resilience
- 39.7.1. Company Snapshot
- 39.7.2. Interview Transcript: Former Senior Director of Commercial Strategy and Market Insights
39.8. Minaris Regenerative Medicine
- 39.8.1. Company Snapshot
- 39.8.2. Interview Transcript: Former Global Head of Sales and Marketing and Head of Business Development (Germany)
39.9. 53Biologics
- 39.9.1. Company Snapshot
- 39.9.2. Interview Transcript: Business Development Manager
39.10. Richter-Helm BioLogics
- 39.10.1. Company Snapshot
- 39.10.2. Interview Transcript: Manager Marketing and Sales

40. APPENDIX I: TABULATED DATA

41. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

簡介目錄圖表

List of Tables

Table 6.1 Mammalian versus Microbial Expression Systems
Table 7.1 List of Biopharmaceutical Contract Manufacturers: Information on Year of Establishment, Company Size, Location of Headquarters
Table 7.2 Key Biopharmaceutical Contract Manufacturers: Information on Compliance and Type of Service Offered
Table 7.3 Key Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 7.4 Key Biopharmaceutical Contract Manufacturers: Information on Scale of Operation and Type of Expression System Used
Table 7.5 Key Biopharmaceutical Contract Manufacturers: Information on Type of Primary Container Offered
Table 8.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 8.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 8.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 8.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 9.1 Biopharmaceutical Contract Manufacturers: List of Companies Profiled
Table 9.2 AbbVie: Company Overview
Table 9.3 AbbVie: Service Portfolio
Table 9.4 Agilent Technologies: Company Overview
Table 9.5 Agilent Technologies: Service Portfolio
Table 9.6 Catalent: Company Overview
Table 9.7 Catalent: Service Portfolio
Table 9.8 Boehringer Ingelheim: Company Overview
Table 9.9 Boehringer Ingelheim: Service Portfolio
Table 9.10 Eurofins: Company Overview
Table 9.11 Eurofins: Service Portfolio
Table 9.12 Fresenius Kabi: Company Overview
Table 9.13 Fresenius Kabi: Service Portfolio
Table 9.14 Lonza: Company Overview
Table 9.15 Lonza: Service Portfolio
Table 9.16 Novartis: Company Overview
Table 9.17 Novartis: Service Portfolio
Table 9.18 Sandoz: Company Overview
Table 9.19 Sandoz: Service Portfolio
Table 9.20 WACKER: Company Overview
Table 9.21 WACKER: Service Portfolio
Table 9.22 Cipla: Company Overview
Table 9.23 Cipla: Service Portfolio
Table 9.24 WuXi Biologics: Company Overview
Table 9.25 WuXi Biologics: Service Portfolio
Table 10.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Developer, Phase of Development and Target Antigen
Table 10.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segments
Table 10.3 Bispecific Antibody Therapeutics: Information on Preclinical Drug Candidate, Developer, Stage of Development and Target Antigen
Table 10.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 10.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 10.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 10.7 Antibody-Drug Conjugates: Information on Developer, Stage of Development, Target Indication and Therapeutic Area
Table 10.8 Antibody-Drug Conjugate Developers: Information on Year of Establishment, Location of Headquarters (Country / Region), and Company Size
Table 10.9 ADC Contract Manufacturers: List of Companies
Table 10.10 Cell-based Therapies: Applications
Table 10.11 Cell-based Therapies: Commercialized Products
Table 10.12 Assessments for Key Cell Therapy Manufacturing Steps
Table 10.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 10.14 Industry Players: Information on Type of Immune Cell Offered
Table 10.15 Cell / Gene Therapy Contract Manufacturers: List of Companies
Table 10.16 Viral Vector and Gene Therapy Manufacturers (Industry Players): Information on Type of Viral Vector Manufactured
Table 10.17 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 10.18 Plasmid DNA Contract Manufacturers: List of Companies
Table 11.1 List of Biosimilars Contract Manufacturing Service Providers
Table 12.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 12.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 12.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 13.1 List of FDA Approved Biologics (2016-2024)
Table 15.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations
Table 15.2 Partnerships and Collaborations: Information on Scale of Operation and Therapeutic Area
Table 15.3 Partnerships and Collaborations: Information on Location of Headquarters (Country and Region) and Type of Agreement (Country and Region)
Table 16.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, Q1 2024 - Q4 2025
Table 17.1 Biopharmaceutical Contract Manufacturing Organizations: List of Mergers and Acquisitions, Q1 2024 - Q4 2025
Table 17.2 Mergers and Acquisitions: Information on Key Value Drivers
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Expansions
Table 19.1 List of Top Seven Big Pharma Players
Table 19.2 Big Pharma Players: List of Biopharmaceutical Contract Manufacturing Focused Initiatives, Q1 2024 - Q4 2025
Table 20.1 Biopharmaceutical Contract Manufacturers: Information on Mammalian and Microbial Production Capacities (Sample Dataset)
Table 20.2 Biopharmaceutical Contract Manufacturing: Average Mammalian and Microbial Production Capacity Based on Company Size
Table 20.3 Biopharmaceutical Contract Manufacturers: Information on Production Capacity (Sample Dataset)
Table 20.4 Biopharmaceutical Contract Manufacturing: Average Production Capacity Based on Company Size (Sample Dataset)
Table 20.5 Global Biopharmaceutical Contract Manufacturing Capacity: Distribution by Company Size (in liters)
Table 22.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 22.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 35.1 RoslinCT: Key Highlights
Table 35.2 JAFRAL Biosolutions: Key Highlights
Table 35.3 Discovery Life Sciences: Key Highlights
Table 35.4 Bioworkshops: Key Highlights
Table 35.5 Aldevron: Key Highlights
Table 35.6 Resilience: Key Highlights
Table 35.7 Minaris Regenerative Medicine: Key Highlights
Table 35.8 53Biologics: Key Highlights
Table 35.9 Richter-Helm BioLogics: Key Highlights
Table 40.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 40.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 40.3 Biopharmaceutical CMOs: Distribution by Location of Headquarters (Region)
Table 40.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 40.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
Table 40.6 Biopharmaceutical Contract Manufacturers: Distribution by Compliance
Table 40.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 40.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 40.9 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 40.10 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 40.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 40.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Primary Container Offered
Table 40.13 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 40.14 Biopharmaceutical Contract Manufacturing Facilities: Distribution of Type of Service Offered
Table 40.15 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 40.16 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 40.17 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Table 40.18 Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Table 40.19 Antibody-Drug Conjugates: Distribution by Stage of Development
Table 40.20 Antibody-Drug Conjugates: Distribution by Target Indication
Table 40.21 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Table 40.22 Industry Players: Distribution by Type of Immune Cell Offered
Table 40.23 Marketed and Clinical Stage Gene Therapies: Distribution by Stage of Development
Table 40.24 Marketed and Clinical Stage Gene Therapies: Distribution by Type of Vector Used
Table 40.25 Preclinical and Discovery Stage Gene Therapies: Distribution by Therapeutic Area
Table 40.26 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Table 40.27 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Table 40.28 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 40.29 Biosimilars: Historical Trend of FDA Approvals, 2015-2025
Table 40.30 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Table 40.31 Partnerships and Collaborations: Cumulative Trend of Partnerships, Q1 2024 - Q4 2025
Table 40.32 Partnerships and Collaborations: Distribution by Type of Partnership
Table 40.33 Partnerships and Collaborations: Distribution of Quarter and Type of Partnership
Table 40.34 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 40.35 Partnerships and Collaborations: Distribution by Scale of Operation
Table 40.36 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 40.37 Most Active Players: Distribution by Number of Partnerships
Table 40.38 Partnerships and Collaborations: Local and International Agreements
Table 40.39 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 40.40 Funding and Investments: Cumulative Trend of Funding, Q1 2024 - Q4 2025
Table 40.41 Funding and Investments: Cumulative Trend of Amount Invested, Q1 2024 - Q4 2025 (USD Million)
Table 40.42 Funding and Investments: Distribution of Instances by Type of Funding
Table 40.43 Funding and Investments: Distribution by Quarter and Type of Funding, Q1 2024 - Q4 2025 (USD Million)
Table 40.44 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 40.45 Funding and Investments: Distribution by Geography (Region)
Table 40.46 Funding and Investments: Distribution by Geography (Country)
Table 40.47 Most Active Players: Distribution by Number of Funding Instances
Table 40.48 Most Active Players: Distribution by Amount Raised (USD Million)
Table 40.49 Mergers and Acquisitions: Cumulative Trend of Mergers and Acquisitions, Q1 2024 - Q4 2025
Table 40.50 Mergers and Acquisitions: Distribution by Type of Agreement
Table 40.51 Mergers and Acquisitions: Distribution by Local and International Agreements
Table 40.52 Mergers and Acquisitions: Distribution by Intracontinental and Intercontinental Agreements
Table 40.53 Most Active Players: Distribution by Number of Agreements
Table 40.54 Mergers and Acquisitions: Distribution by Ownership Change Matrix
Table 40.55 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 40.56 Recent Expansions: Distribution by Cumulative Trend of Expansions
Table 40.57 Recent Expansions: Distribution by Type of Expansion
Table 40.58 Recent Expansions: Distribution by Year and Type of Expansion
Table 40.59 Recent Expansions: Distribution by Location of Facility (Region)
Table 40.60 Recent Expansions: Distribution by Location of Facility (Country)
Table 40.61 Recent Expansions: Distribution by Distribution by Type of Expansion and Location of Facility (Region)
Table 40.62 Recent Expansions: Distribution of Amount Invested by Year of Expansion
Table 40.63 Recent Expansions: Distribution of Amount Invested by Type of Expansion
Table 40.64 Most Active Players: Distribution by Number of Expansions
Table 40.65 Most Active Players: Distribution by Amount Invested
Table 40.66 Big Pharma Initiatives: Cumulative Trend of Initiatives
Table 40.67 Big Pharma Initiatives: Distribution by Type of Initiative
Table 40.68 Big Pharma Initiatives: Distribution by Quarter and Type of Initiative
Table 40.69 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Table 40.70 Big Pharma Initiatives: Distribution by Type of Partnership
Table 40.71 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Table 40.72 Big Pharma Initiatives: Distribution by Type of Acquisition
Table 40.73 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Table 40.74 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Expansions
Table 40.75 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Company Size
Table 40.76 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Type of Expression System Used
Table 40.77 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Geography
Table 40.78 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 40.79 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 40.80 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 40.81 Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 40.82 Global Demand for Biopharmaceutical Contract Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Table 40.83 Global Demand for Biopharmaceuticals: Distribution by Scale of Operation, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Table 40.84 Global Demand for ADC Therapeutics, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in kilograms)
Table 40.85 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Table 40.86 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Cells)
Table 40.87 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 40.88 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution of CAPEX (USD Million)
Table 40.89 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 40.90 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 40.91 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution of CAPEX (USD Million)
Table 40.92 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 40.93 Global Biologics Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.94 Global Biologics Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Table 40.95 Biologics Contract Manufacturing Market: Distribution by Type of Service Offered
Table 40.96 Biologics Contract Manufacturing Market for Drug Substance (API) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.97 Biologics Contract Manufacturing Market for Drug Product (FDF) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.98 Biologics Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Table 40.99 Biologics Contract Manufacturing Market for Antibodies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.100 Biologics Contract Manufacturing Market for Proteins / Peptides, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.101 Biologics Contract Manufacturing Market for Vaccines, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.102 Biologics Contract Manufacturing Market for Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (2025-2035) (USD Billion)
Table 40.103 Biologics Contract Manufacturing Market for Gene Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.104 Biologics Contract Manufacturing Market for Other Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.105 Biologics Contract Manufacturing Market: Distribution by Type of Expression System Used
Table 40.106 Biologics Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.107 Biologics Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.108 Biologics Contract Manufacturing Market for Other Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.109 Biologics Contract Manufacturing Market: Distribution by Scale of Operation
Table 40.110 Biologics Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.111 Biologics Contract Manufacturing Market for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.112 Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
Table 40.113 Biologics Contract Manufacturing Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.114 Biologics Contract Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.115 Biologics Contract Manufacturing Market for Metabolic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.116 Biologics Contract Manufacturing Market for Infectious Diseases, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.117 Biologics Contract Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.118 Biologics Contract Manufacturing Market for Neurological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.119 Biologics Contract Manufacturing Market for Genetic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.120 Biologics Contract Manufacturing Market for Other Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.121 Biologics Contract Manufacturing Market: Distribution by Company Size
Table 40.122 Biologics Contract Manufacturing Market for Small Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.123 Biologics Contract Manufacturing Market for Mid-sized Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.124 Biologics Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.125 Biologics Contract Manufacturing Market: Distribution by Key Geographical Regions
Table 40.126 Biologics Contract Manufacturing Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.127 Biologics Contract Manufacturing Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.128 Biologics Contract Manufacturing Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.129 Biologics Contract Manufacturing Market in Puerto Rico, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.130 Biologics Contract Manufacturing Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.131 Biologics Contract Manufacturing Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.132 Biologics Contract Manufacturing Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.133 Biologics Contract Manufacturing Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.134 Biologics Contract Manufacturing Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.135 Biologics Contract Manufacturing Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.136 Biologics Contract Manufacturing Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.137 Biologics Contract Manufacturing Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.138 Biologics Contract Manufacturing Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.139 Biologics Contract Manufacturing Market in South Korea, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.140 Biologics Contract Manufacturing Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.141 Biologics Contract Manufacturing Market in Singapore, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.142 Biologics Contract Manufacturing Market in Rest of the Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.143 Biologics Contract Manufacturing Market in Rest of the World, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.144 Biologics Contract Manufacturing Market in Israel, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.145 Biologics Contract Manufacturing Market in Argentina, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.146 Biologics Contract Manufacturing Market in Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Table 40.147 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Table 40.148 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market in 2023 (USD Billion)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 4.1 Lessons Learnt from Past Recessions
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Forecast and Opportunity Analysis
Figure 6.1 Types of Biopharmaceuticals
Figure 6.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 6.3 Stages of the Biomanufacturing Process
Figure 6.4 Types of Third Party Service Providers
Figure 6.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 7.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 7.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 7.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 7.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 7.5 Biopharmaceutical Contract Manufacturers: Distribution by Company Size and Location of Headquarters (Region)
Figure 7.6 Key Biopharmaceutical Contract Manufacturers: Distribution by Compliance
Figure 7.7 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Figure 7.8 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 7.9 Key Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 7.10 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 7.11 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 7.12 Key Biopharmaceutical Contract Manufacturers: Distribution by Type of Primary Container Offered
Figure 8.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 8.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Figure 8.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 8.4 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
Figure 8.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
Figure 8.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Figure 8.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Figure 10.1 Basic Structure of an Antibody
Figure 10.2 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 10.3 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target indication
Figure 10.4 Preclinical Bispecific Antibody Therapeutics: Distribution by Stage of Development
Figure 10.5 Structure of an Antibody Drug Conjugate (ADC)
Figure 10.6 Antibody-Drug Conjugates: Distribution by Stage of Development
Figure 10.7 Antibody-Drug Conjugates: Distribution by Target Indication
Figure 10.8 Most Active Players: Distribution by Number of Antibody-Drug Conjugates
Figure 10.9 Decentralized Manufacturing: Process Model
Figure 10.10 Cell Therapy Manufacturing: Types of Manufacturers
Figure 10.11 Cell Therapies: Challenges and Drivers
Figure 10.12 Cell Therapies: Potency as Critical Quality Attribute
Figure 10.13 Industry Players: Distribution by Type of Immune Cell Offered
Figure 10.14 Marketed and Clinical Stage Gene Therapies: Distribution by Stage of Development
Figure 10.15 Marketed and Clinical Stage Gene Therapies: Distribution by Type of Vector Used
Figure 10.16 Marketed and Clinical Stage Gene Therapies: Distribution by Therapeutic Area
Figure 10.17 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Vector Manufacturing Facility (Region)
Figure 10.18 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Type of Viral Vector Manufactured
Figure 10.19 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 11.1 Manufacturing Stages of a Biosimilar Product
Figure 11.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 11.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 11.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 11.5 Biosimilars: Historical Trend of FDA Approvals, 2015-2025
Figure 11.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 12.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2024
Figure 12.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 13.1 Benefits Associated with In-House Manufacturing
Figure 13.2 Risks Associated with In-House Manufacturing
Figure 13.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 14.1 Make versus Buy Decision Making Framework
Figure 14.2 Make versus Buy Decision Making Framework: Possible Scenarios
Figure 15.1 Partnerships and Collaborations: Cumulative Trend of Partnerships, Q1 2024 - Q4 2025
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Quarter and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 15.5 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 15.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 15.7 Most Active Players: Distribution by Number of Partnerships
Figure 15.8 Partnerships and Collaborations: Local and International Agreements
Figure 15.9 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 16.1 Funding and Investments Analysis: Cumulative Trend of Funding, Q1 2024 - Q4 2025
Figure 16.2 Funding and Investments Analysis: Cumulative Trend of Amount Invested, Q1 2024 - Q4 2025 (USD Million)
Figure 16.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 16.4 Funding and Investment Analysis: Distribution by Quarter and Type of Funding, Q1 2024 - Q4 2025
Figure 16.5 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 16.6 Funding and Investment Analysis: Distribution of Amount Invested by Quarter and Type of Funding, Q1 2024 - Q4 2025
Figure 16.7 Funding and Investment Analysis: Distribution by Geography (Region)
Figure 16.8 Funding and Investment Analysis: Distribution by Geography (Country)
Figure 16.9 Most Active Players: Distribution by Number of Funding Instances
Figure 16.10 Most Active Players: Distribution by Amount Raised (USD Million)
Figure 17.1 Mergers and Acquisitions: Cumulative Trend of Mergers and Acquisitions, Q1 2024 - Q4 2025
Figure 17.2 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 17.3 Mergers and Acquisitions: Distribution by Local and International Agreements
Figure 17.4 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements
Figure 17.5 Most Active Players: Analysis by Number of Agreements
Figure 17.6 Mergers and Acquisitions: Ownership Change Matrix
Figure 17.7 Mergers and Acquisitions: Key Value Drivers
Figure 18.1 Recent Expansions: Cumulative Trend of Expansions, Q1 2024 - Q4 2025
Figure 18.2 Recent Expansions: Distribution by Type of Expansion
Figure 18.3 Recent Expansions: Distribution by Quarter and Type of Expansion
Figure 18.4 Recent Expansions: Distribution by Location of Facility (Region)
Figure 18.5 Recent Expansions: Distribution by Location of Facility (Country)
Figure 18.6 Recent Expansions: Distribution by Type of Expansion and Location of Facility (Region)
Figure 18.7 Recent Expansions: Distribution of Amount Invested by Quarter of Expansion
Figure 18.8 Recent Expansions: Distribution of Amount Invested by Type of Expansion
Figure 18.9 Most Active Players: Distribution by Number of Expansions
Figure 18.10 Most Active Players: Distribution by Amount Invested
Figure 19.1 Big Pharma Initiatives: Cumulative Trend of Big Pharma Initiatives
Figure 19.2 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 19.3 Big Pharma Initiatives: Distribution by Quarter and Type of Initiative
Figure 19.4 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Initiatives
Figure 19.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 19.6 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Partnerships
Figure 19.7 Big Pharma Initiatives: Distribution by Type of Acquisition
Figure 19.8 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Mergers and Acquisitions
Figure 19.9 Big Pharma Initiatives: Distribution of Big Pharma Players by Number of Expansions
Figure 19.10 Big Pharma Initiatives Summary
Figure 20.1 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Company Size
Figure 20.2 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Type of Expression System Used
Figure 20.3 Global Capacity of Biopharmaceutical Contract Manufacturers (in liters): Distribution by Geography
Figure 20.4 Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 20.5 Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 20.6 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Figure 20.7 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Figure 21.1 Global Demand for Biopharmaceutical Contract Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Figure 21.2 Global Demand for Biopharmaceutical Contract Manufacturing: Distribution by Scale of Operation, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in million liters)
Figure 21.3 Global Demand for ADC Therapeutics, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in kilograms)
Figure 21.4 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Patients)
Figure 21.5 Global Demand for Cell Therapy Manufacturing, Historical Trends (since 2024) and Forecasted Estimates (till 2035) (in terms of Number of Cells in Billion)
Figure 22.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 22.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 22.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 22.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 23.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 24.1 Global Biologics Contract Manufacturing Market, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 24.2 Global Biologics Contract Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Figure 24.3 Global Biologics Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Figure 25.1 Biologics Contract Manufacturing Market: Distribution by Type of Service Offered
Figure 25.2 Biologics Contract Manufacturing Market for Drug Substance (API) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.3 Biologics Contract Manufacturing Market for Drug Product (FDF) Manufacturing, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.1 Biologics Contract Manufacturing Market: Distribution by Type of Biologic Manufactured
Figure 26.2 Biologics Contract Manufacturing Market for Antibodies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.3 Biologics Contract Manufacturing Market for Proteins / Peptides, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.4 Biologics Contract Manufacturing Market for Vaccines, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.5 Biologics Contract Manufacturing Market for Cell Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.6 Biologics Contract Manufacturing Market for Gene Therapies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.7 Biologics Contract Manufacturing Market for Other Biologics, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.1 Biologics Contract Manufacturing Market: Distribution by Type of Expression System Used
Figure 27.2 Biologics Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.3 Biologics Contract Manufacturing Market for Microbial Expression System, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.4 Biologics Contract Manufacturing Market for Other Expression System, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Biologics Contract Manufacturing Market: Distribution by Scale of Operation
Figure 28.2 Biologics Contract Manufacturing Market for Preclinical / Clinical Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.3 Biologics Contract Manufacturing Market for Commercial Scale, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.1 Biologics Contract Manufacturing Market: Distribution by Therapeutic Area
Figure 29.2 Biologics Contract Manufacturing Market for Oncological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.3 Biologics Contract Manufacturing Market for Cardiovascular Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.4 Biologics Contract Manufacturing Market for Metabolic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.5 Biologics Contract Manufacturing Market for Infectious Diseases, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.6 Biologics Contract Manufacturing Market for Autoimmune Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.7 Biologics Contract Manufacturing Market for Neurological Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.8 Biologics Contract Manufacturing Market for Genetic Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.9 Biologics Contract Manufacturing Market for Other Disorders, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.1 Biologics Contract Manufacturing Market: Distribution by Company Size
Figure 30.2 Biologics Contract Manufacturing Market for Small Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.3 Biologics Contract Manufacturing Market for Mid-sized Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.4 Biologics Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.1 Biologics Contract Manufacturing Market: Distribution by Key Geographical Regions
Figure 31.2 Biologics Contract Manufacturing Market in North America, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.3 Biologics Contract Manufacturing Market in the US, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.4 Biologics Contract Manufacturing Market in Canada, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.5 Biologics Contract Manufacturing Market in Puerto Rico, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.6 Biologics Contract Manufacturing Market in Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.7 Biologics Contract Manufacturing Market in Germany, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.8 Biologics Contract Manufacturing Market in the UK, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.9 Biologics Contract Manufacturing Market in France, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.10 Biologics Contract Manufacturing Market in Spain, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.11 Biologics Contract Manufacturing Market in Italy, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.12 Biologics Contract Manufacturing Market in Rest of Europe, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.13 Biologics Contract Manufacturing Market in Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.14 Biologics Contract Manufacturing Market in China, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.15 Biologics Contract Manufacturing Market in South Korea, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.16 Biologics Contract Manufacturing Market in Japan, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.17 Biologics Contract Manufacturing Market in Singapore, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.18 Biologics Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.19 Biologics Contract Manufacturing Market in Rest of the World, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.20 Biologics Contract Manufacturing Market in Israel, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.21 Biologics Contract Manufacturing Market in Argentina, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.22 Biologics Contract Manufacturing Market in Africa, Historical Trends (since 2022) and Forecasted Estimates (till 2035) (USD Billion)
Figure 31.23 Market Movement Analysis: Key Geographical Regions
Figure 31.24 Penetration-Growth (P-G) Matrix: Key Geographical Regions
Figure 36.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 36.2 Overall Share of Virtual Biopharmaceutical Companies in the Biologics Contract Manufacturing Market in 2023 (USD Billion)
Figure 38.1 Concluding Remarks: Overall Market Landscape
Figure 38.2 Concluding Remarks: Partnerships and Collaborations
Figure 38.3 Concluding Remarks: Funding and Investments
Figure 38.4 Concluding Remarks: Mergers and Acquisitions
Figure 38.5 Concluding Remarks: Recent Expansions
Figure 38.6 Concluding Remarks: Capacity Analysis
Figure 38.7 Concluding Remarks: Demand Analysis
Figure 38.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 38.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

02-2729-4219

+886-2-2729-4219

License/價格

相關商品

生物製劑契約製造市場：全球預測，2026-2032年

生技藥品契約製造市場：依服務類型、生技藥品類型、生產系統、規模、公司規模、治療領域及地區分類

生物製劑契約製造市場分析及預測（至2035年）：類型、產品、服務、技術、應用、最終用戶、製程、安裝類型、設備和階段

全球生物製劑契約製造市場規模、佔有率、趨勢和成長分析報告（2026-2034）

中國生物製劑合約生產市場：產業趨勢及全球預測 - 依產品類型、所用表達系統、業務規模、公司規模、生物製劑類型劃分

生技藥品契約製造市場規模、佔有率、趨勢分析報告：按產品、適應症、地區、細分市場預測，2025-2030 年

FAQ

生物製藥契約製造市場（第七版）：按服務類型、生產的生物製劑類型、使用的表達系統、業務規模、公司規模、治療領域和主要區域分類的趨勢和預測（至2035年）

Biologics Contract Manufacturing Market (7th Edition) by Type of Service Offered, Type of Biologic Manufactured, Expression System Used, Scale of Operation, Company Size, Therapeutic Area, Key Geographical Regions - Trends and Forecast, Till 2035

生物製藥契約製造市場概覽

生物製藥契約製造市場主要公司範例

第一次調查總結

目錄

第1章：序言

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

第6章：引言

第7章 市場狀況

第8章：區域能力分析

第9章：公司簡介

第10章生物製藥的主要領域

第11章案例研究：生物相似藥外包

第12章案例研究：小分子藥物與大分子藥物/治療方法的比較

第13章案例研究：內部製造

第14章：製造與採購之間的決策框架

第15章夥伴關係與合作

第16章資金籌措與投資分析

第17章併購

第18章 近期擴張

第19章：主要製藥公司的舉措

第20章 能力分析

第21章 需求分析

第22章 總擁有成本

第23章 SWOT分析

第24章：全球生物製藥契約製造市場

第25章：生物製藥契約製造市場（依服務類型分類）

第26章：生物製藥契約製造市場（依生產的生物製藥類型分類）

第27章：生物製藥的契約製造市場（依表達系統類型分類）

第28章：生物製藥契約製造市場（依企業規模分類）

第29章：生物製藥契約製造市場（依公司規模分類）

第30章：生物製藥契約製造市場（依治療領域分類）

第31章：生物製藥契約製造市場（依主要地區分類）

第32章：生物製藥契約製造市場：北美

第33章：生物製藥契約製造市場：歐洲

第34章：生物製藥契約製造市場：亞太地區

第35章：生物製藥契約製造市場：其他地區

第36章案例研究：虛擬製藥公司

第37章：生物製藥CMO市場的未來展望

第38章 結論

第39章：高階主管洞察

第40章 附錄一：表格形式數據

第41章 附錄二：公司與組織列表

Biologics Contract Manufacturing Market: Overview

Example Players in the Biologics Contract Manufacturing Market

Primary Research Overview

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. MARKET LANDSCAPE

8. REGIONAL CAPABILITY ANALYSIS

9. COMPANY PROFILES

10. PROMINENT BIOPHARMACEUTICAL SECTORS

11. CASE STUDY: OUTSOURCING OF BIOSIMILARS

12. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

13. CASE STUDY: IN-HOUSE MANUFACTURING

14. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

15. PARTNERSHIPS AND COLLABORATIONS

16. FUNDING AND INVESTMENTS ANALYSIS

17. MERGERS AND ACQUISITIONS

18. RECENT EXPANSIONS

19. BIG PHARMA INITIATIVES

20. CAPACITY ANALYSIS

21. DEMAND ANALYSIS

22. TOTAL COST OF OWNERSHIP

23. SWOT ANALYSIS

24. GLOBAL BIOLOGICS CONTRACT MANUFACTURING MARKET

25. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED

26. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

27. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

28. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

29. BIOLOGICS CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

第3章市場動態

第4章宏觀經濟指標

第7章市場狀況

第18章近期擴張

第20章能力分析

第21章需求分析

第22章總擁有成本

第38章結論

第40章附錄一：表格形式數據

第41章附錄二：公司與組織列表